PGP and atrial fibrillation: For distribution of dose reduction criteria, ETNA-AF-China revealed that in evaluable patients who met the dose reduction criteria (including recommended and non-recommended doses), 81.4% (n = 1491/1832) had a body weight of ≤ 60 kg, 45.9% (n = 841/1832) presented a CrCl value of ≤ 50 mL/min, and 0.9% (n = 16/1832) were categorised with concomitant use of the label-listed P-gp inhibitor.